Lv5
1350 积分 2022-07-07 加入
Discovery of novel MAT2A inhibitors by an allosteric site-compatible fragment growing approach
2个月前
已完结
Discovery of macrocyclic CDK2/4/6 inhibitors with improved potency and DMPK properties through a highly efficient macrocyclic drug design platform
2个月前
已完结
Discovery of Potent, Highly Selective, and Orally Bioavailable MTA Cooperative PRMT5 Inhibitors with Robust In Vivo Antitumor Activity
2个月前
已完结
Discovery and Biological Evaluation of Novel, Potent, and Orally Available CBLB Inhibitors
2个月前
已完结
Phase Ib Pharmacodynamic Study of the MNK Inhibitor Tomivosertib (eFT508) Combined With Paclitaxel in Patients With Refractory Metastatic Breast Cancer
3个月前
已完结
Phase Ib Pharmacodynamic Study of the MNK Inhibitor Tomivosertib (eFT508) Combined With Paclitaxel in Patients With Refractory Metastatic Breast Cancer
3个月前
已完结
MNK, mTOR or eIF4E-selecting the best anti-tumor target for blocking translation initiation
3个月前
已完结
TSC2 loss in neural progenitor cells suppresses mRNA translation of neurodevelopmental genes
3个月前
已完结
Structure-based Design of Pyridone–Aminal eFT508 Targeting Dysregulated Translation by Selective Mitogen-activated Protein Kinase Interacting Kinases 1 and 2 (MNK1/2) Inhibition
3个月前
已完结
Update on the Development of MNK Inhibitors as Therapeutic Agents
3个月前
已完结
皖公网安备34019202002308
